Use of antidiabetics for making a medicine with cicatrizing effect

• US 20040147430A1
• Filed: 12/04/2003
• Published: 07/29/2004
• Est. Priority Date: 06/20/2001
• Status: Abandoned Application

• Current Assignee: Merck Sante
• Original Assignee: Merck Sante
• Inventors: Briet, Philippe
• Application Number:
  US10/479,615
• Publication Number:
  US 20040147430A1
• Time in Patent Office: Days
• US Class Current: 514/3
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/197 the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid carnitine A61K31/205
• CPC Class Codes: A61K 31/426 1,3-Thiazoles
• CPC Class Codes: A61K 31/427 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 31/4439 containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole nicotine A61K31/465
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 31/451 having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
• CPC Class Codes: A61K 31/64 Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
• CPC Class Codes: A61K 31/702 Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61K 38/47 acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

The invention concerns the use of at least an antidiabetic selected among compounds stimulation insulin secretion, glucosidase inhibitors, thiazolidine-diones, insulin, agents enhancing insulin sensitivity, the glucagon-like peptide-1 (GLP-1), PPARα/γ agonists, meglitinide and aP2 inhibitors for making a medicine with cicatrizing effect.

Claims

1. The use of at least one antidiabetic chosen from compounds stimulating the secretion of insulin, glucosidase inhibitors, thiazolidinediones, insulin, agents enhancing sensitivity to insulin, glucagon-like peptide-1 (GLP-1), PPAR α

/γ

agonists, meglitinide and aP2 inhibitors, for manufacturing a medicine having a cicatrizing effect.

2. The use as claimed in claim 1, for manufacturing a medicine having a cicatrizing effect in a pharmaceutical dosage form for topical use.

3. The use as claimed in claim 2, for manufacturing a medicine having a cicatrizing effect in a pharmaceutical dosage form for topical use intended to be applied to the skin.

4. The use as claimed in any one of the preceding claims, for manufacturing a medicine having a cicatrizing effect on the wounds of diabetic subjects.

5. The use as claimed in any one of the preceding claims, characterized in that the compounds stimulating the secretion of insulin are selected from sulfonylureas and repaglinide, nateglinide or nitiglinide.

6. The use as claimed in the preceding claim, characterized in that the sulfonylureas are selected from acetohexamide, carbutamide, gliquidone, glisentide, glisolamide, glisoxepide, glycyclamide, glibornuride, chlorpropamide, tolazamide, tolbutamide, tolcyclamide, glipizide, gliclazide, glimepiride and glibenclamide.

7. The use as claimed in one of claims 1 to 4, characterized in that the glucosidase inhibitor is chosen from acarbose, vaglibose and miglitol.

8. The use as claimed in one of claims 1 to 4, characterized in that the thiazolidinediones and the other agents promoting the sensitivity to insulin are chosen from troglitazone, Rosiglitazone, Pioglitazone, MCC-555, GL-262570, englitazone and darglitazone.

9. The use as claimed in one of claims 1 to 4, characterized in that the thiazolidinedione is a compound of formula (I) defined in the following manner:

10. The use as claimed in one of claims 1 to 4, characterized in that the PPAR α

/γ

agonists are N-benzyldioxothiazolidylbenzamide derivatives.

11. The use as claimed in any one of the preceding claims, characterized in that the antidiabetic defined according to one of the preceding claims is combined with at least one other active ingredient.